Prosecution Insights
Last updated: August 06, 2026

Promega Corporation

12 pending office actions • 10 art units • 10 examiners • 0 of 12 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days

Portfolio Summary

12
Total Pending OAs
10
Non-Final OAs
2
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (50%)
6
Medium (50%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only3 (25%)
Double-patenting + other3 (25%)
Multi-statute (no §101)6 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

12
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

120 h
Manual time on pending OAs
24 h
Time saved (low, 20%)
42 h
Time saved (mid, 35%)
1.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BOWERS, ERIN M 3 55.1% +10.5%
STEADMAN, DAVID J 1 57.7% +29.5%
MISHRA, DEEPA 1 29.5% +32.2%
BERKELEY, EMILY R 1 76.0% +28.0%
WHITE, DAWANNA SHAR-DAY 1 62.8% +19.6%
PAK, YONG D 1 74.6% +14.2%
RILEY, JEZIA 1 82.9% +7.3%
WARD, PAUL V 1 83.1% -11.6%
VU, JAKE MINH 1 40.6% +27.4%
GRAY, JESSICA 1 0.0% +0.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18176918 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF RILEY, JEZIA

Hard Cases (7)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
18252083 IMPROVED SMALL MOLECULES WHITE, DAWANNA SHAR-DAY 31d overdue
18312487 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING BOWERS, ERIN M 12d
18311977 CIRCULARLY PERMUTED DEHALOGENASE VARIANTS PAK, YONG D 23d
18457679 RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER MISHRA, DEEPA
18447907 BIOCOMPATIBLE OXYGEN-SENSITIVE MATERIALS BERKELEY, EMILY R
18169326 OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS WARD, PAUL V
18054841 CATION EXCHANGE FOR SPERM-ASSOCIATED DNA PURIFICATION GRAY, JESSICA

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
18252083 IMPROVED SMALL MOLECULES WHITE, DAWANNA SHAR-DAY 31d overdue
18312487 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING BOWERS, ERIN M 12d
18311977 CIRCULARLY PERMUTED DEHALOGENASE VARIANTS PAK, YONG D 23d
18812371 ENHANCEMENT OF KINASE TARGET ENGAGEMENT STEADMAN, DAVID J
18655005 COMPLEMENTATION-BASED TAGS AND REPORTERS FOR DUAL-MODALITY LABELING BOWERS, ERIN M
18457679 RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER MISHRA, DEEPA
18447907 BIOCOMPATIBLE OXYGEN-SENSITIVE MATERIALS BERKELEY, EMILY R
18312117 SPLIT MODIFIED DEHALOGENASE VARIANTS BOWERS, ERIN M

Top Art Units

Art UnitApps
1653 3
1656 1
1657 1
1796 1
1627 1
1652 1
1681 1
1622 1
1618 1
1682 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18812371 ENHANCEMENT OF KINASE TARGET ENGAGEMENT STEADMAN, DAVID J 1656 §103DPOther Non-Final OA Pending Aug 22, 2024
18655005 COMPLEMENTATION-BASED TAGS AND REPORTERS FOR DUAL-MODALITY LABELING BOWERS, ERIN M 1653 §103 Non-Final OA Pending May 03, 2024
18457679 RECOGNITION OF CELLULAR TARGET BINDING BY A BIOACTIVE AGENT USING INTRACELLULAR BIOLUMINESCENCE RESONANCE ENERGY TRANSFER MISHRA, DEEPA 1657 §103§112 Non-Final OA Pending Aug 29, 2023
18447907 BIOCOMPATIBLE OXYGEN-SENSITIVE MATERIALS BERKELEY, EMILY R 1796 §102§112 Non-Final OA Pending Aug 10, 2023
18252083 IMPROVED SMALL MOLECULES WHITE, DAWANNA SHAR-DAY 1627 §103§112 Non-Final OA 31d overdue Pending May 08, 2023
18312487 BIOLUMINESCENCE-TRIGGERED PHOTOCATALYTIC LABELING BOWERS, ERIN M 1653 §102§112Other Non-Final OA 12d Pending May 04, 2023
18311977 CIRCULARLY PERMUTED DEHALOGENASE VARIANTS PAK, YONG D 1652 §103§112Other Non-Final OA 23d Pending May 04, 2023
18312117 SPLIT MODIFIED DEHALOGENASE VARIANTS BOWERS, ERIN M 1653 §103 Non-Final OA Pending May 04, 2023
18176918 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF RILEY, JEZIA 1681 §102§112DP Non-Final OA Pending Mar 01, 2023
18169326 OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS WARD, PAUL V 1622 §103§112 Non-Final OA Pending Feb 15, 2023
18057578 COMPOSITIONS AND METHODS FOR STABILIZING COELENTERAZINE AND ANALOGS AND DERIVATIVES THEREOF VU, JAKE MINH 1618 §103Other Final Rejection Pending Nov 21, 2022
18054841 CATION EXCHANGE FOR SPERM-ASSOCIATED DNA PURIFICATION GRAY, JESSICA 1682 §103DP Final Rejection Pending Nov 11, 2022

Managing Promega Corporation's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month